NAGE

Over the past six months, Niagen Bioscience's stock (NAGE) has experienced a significant decline, falling by approximately 30.11% in the last six months and 70.06% over the past year, with the stock price at $3.00 per share as of September 16, 2026. Key events include the Q2 2026 financial results reported on August 4, 2026, showing net sales of $29.8 million (a 4% decrease year-over-year) and net income of $1.0 million, which matched analyst consensus for income but slightly missed revenue estimates. Strategic moves included selling its analytical reference standards and services segment for $6.0 million in February 2026, resolving a product recall dispute in Asia in April 2026, launching a clinician-directed telehealth platform in May 2026, introducing NB4168 as a lead investigational drug candidate in July 2026, and expanding Tru Niagen's retail footprint to Walmart.com, GNC, and Sam's Club in August 2026. Analyst sentiment as of September 24, 2026, indicates an average 'Buy' recommendation with a 12-month price target of $10.33. The company also has a share repurchase program, having repurchased $2.8 million in the first half of 2026. A preclinical study published on September 21, 2026, demonstrated CD38 as a driver of age-related NAD+ decline and showed that NAD+ restoration with Nicotinamide Riboside (NR) improves pregnancy outcomes. On September 17, 2026, Niagen Bioscience announced it engaged veteran pharmaceutical executives and biotechnology experts to support its drug development program and strategic business growth.